Little did I realize a few grapes could send my blood sugar soaring until I tried the first glucose monitor without a ...

Stock analysis is all about predictions – but as wits from Mark Twain to Yogi Berra have reminded us, predictions are hard, ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...

Now, people without health insurance coverage for such devices have the option to buy Stelo directly from Dexcom’s website. The device is geared toward adults 18 years and older with type 2 ...

After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now ...

DexCom stock has fallen 41% this year, but investor sentiment for the maker of glucose monitoring devices could be changing. SAN DIEGO, August 28, 2024--DexCom, Inc. (NASDAQ:DXCM) today announced ...

As a leading CGM maker, DexCom is likely to play a significant role in diabetes care for years, possibly decades. Given all ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

DexCom stock has fallen 41% this year, but investor sentiment for the maker of glucose monitoring devices could be changing.

The company, which manufactures CGM devices, partnered with Allison PR for a campaign that aimed to spread awareness of life ...